MolecuLight Secures $11.7 Million in Funding to Accelerate Global Expansion Page 1

TORONTO, August 15, 2024 /PRNewswire/ — MolecuLight Inc., a leader in point-of-care fluorescence imaging, today announced the closing of a $11.7 million Series C funding round led by new investors Export Development Canada (EDC), Prosegur and Azahar. Existing investors also participated in the round, showing continued confidence in the company’s growth trajectory.

MolecuLight’s fluorescence imaging devices provide clinicians with real-time visualization of bacterial fluorescence in wounds, enabling earlier detection and quantification, leading to more effective treatment and improved wound healing. MolecuLight’s wound bed assessment aligns perfectly with CTP results: a study by Ai-Jalodi and colleagues shows that when the device indicates a bacteria-free wound bed, there is a 100% chance of CTP integration¹versus a skin substitute alone. By empowering healthcare providers to make informed decisions at the point of care, MolecuLight helps improve patient outcomes and reduce healthcare costs. The new investment will fuel MolecuLight’s expansion in the U.S., Canadaand EU across all care settings, including hospital outpatient clinics, independent wound care clinics, podiatrists, and long-term care facilities. This growth enables the company to reach more patients and positively impact their lives by providing clinicians with the tools to quickly and accurately identify and quantify bacteria that impede wound healing, which in turn improves patient outcomes.

“MolecuLight’s innovative technology has the potential to significantly improve patient outcomes and offers compelling benefits to all stakeholders in the healthcare system,” said Guillermo FreireSenior Vice-President, Mid-Market Group, EDC. “We are excited to invest in MolecuLight as they accelerate commercialization. EDC is focused on supporting emerging Canadian innovators in critical industries that are essential to the future. This investment reflects our belief in innovation and progress, and underscores our mission to support Canadian companies on their journey to become global leaders in their industries.”

“We are pleased to invest in MolecuLight. We believe in MolecuLight’s mission to transform wound care and with their innovative technology,” said Pedro MuñozGeneral Manager at Azahar. “This investment enables MolecuLight to accelerate its expansion efforts to more healthcare providers globally.”